Abstract: Provided is a compound having anti-tumor activity and a use thereof. As a PRMT5 inhibitor, the compound has a structure represented by formula (I). Experiments have confirmed that these compounds have strong inhibitory effects on PRMT5 enzyme activity and tumor cell growth, and can be used as promising compounds for treating PRMT5-mediated diseases. Furthermore, a specific synthesis method is further studied. The synthesis method is simple in process, convenient to operate, and beneficial to large-scale industrial production and application.

Abstract: A crystal form of a compound represented by formula (I), and a preparation therefor and an application thereof are provided. Also disclosed are a variety of crystal forms of the compound represented by formula (I) (especially crystal form A). The crystal forms have the advantages of excellent stability, hygroscopicity and purity, etc., and has great significance for promoting later-stage drug development of the compound represented by formula (I).

Abstract: A compound 5-(3-bromophenyl)-3-((diethylamino)methyl)-5-methylimidazolidine-2,4-dione, its synthesis, use as an antibacterial agent and an inhibitor of Chronic Obstructive Pulmonary Disease (COPD).

Abstract: Novel chemical agents are described herein. More specifically, a novel inhibitor of 17?-HSD7 for decreasing estradiol concentrations while restoring dihydrotestosterone (DHT) concentrations in breast cancer cells is disclosed herein. In a particular embodiment, the inhibitor of 17?-HSD7 has the following structure: (Formula I) A process for producing the novel inhibitors of 17?-HSD7 and their use in the manufacture of pharmaceutical formulations and/or combinations is also disclosed.

Abstract: Aspects of the present disclosure include pharmaceutical compositions, and their methods of use, where the pharmaceutical compositions include an active agent prodrug that provides enzymatically-controlled release of an active agent, and controlled release nafamostat or a pharmaceutically acceptable salt thereof.

Abstract: A laundry detergent composition can include a nonionic surfactant, an amine oxide, and a quaternary ammonium salt biocide, where the composition is micellar.

Abstract: A method for increasing susceptibility of microorganisms to antibiotics includes providing a microorganism; administering a single type of an antibiotic including a nitroimidazole compound to the microorganism; and administering any of an uronic, aldonic, ulosonic, and aldaric feedstock to the microorganism. The feedstock is adapted to promote cell metabolism and antibiotic activation, and inhibit antibiotic inactivation pathways in the microorganism causing increased sensitivity of the microorganism to the nitroimidazole.

Abstract: The present invention discloses a sealing fluid comprising an organic acid, an alcohol and optionally water, the organic acid is lactic acid or acetic acid, the alcohol is isopropanol or ethanol, the sealing fluid is a liquid composition for sealing telescopically joined hard capsules with coaxial partly overlapping body parts.

Abstract: Imidazo[4,5-c]quinoline compounds having a substituent that is attached at the N-1 position by a branched group, single enantiomers of the compounds, pharmaceutical compositions containing the compounds, and methods of making the compounds are disclosed. Methods of use of the compounds as immune response modifiers, for inducing cytokine biosynthesis in humans and animals, and in the treatment of diseases including infectious and neoplastic diseases are also disclosed.

Abstract: Polymorphic forms of lysergic acid diethyl amide (LSD) in crystalline salt forms. A pharmaceutical formulation of polymorphic forms of LSD in crystalline salt forms including pharmaceutically acceptable excipients. Polymorphic forms of LSD free-base. Polymorphic forms of a salt form of LSD.

Abstract: The present disclosure relates to methods of transitioning patients or obese patients being treated with vortioxetine to treatment with a monoamine oxidase inhibitor (MAOI). The methods provided include delaying administration of the MAOI for certain time periods after stopping administration of vortioxetine. The patients or obese patients possess various capabilities of metabolizing vortioxetine. The current disclosure also includes methods of switching patients to a MAOI intended to treat psychiatric disorders while being treated with vortioxetine. The methods disclosed further comprise determining vortioxetine plasma clearance and washout time for patients with different body fat status and/or different CYP2D6 metabolizer status.

Abstract: An emulsifiable concentrate comprising a high content of abamectin is provided. The concentrate includes an amide solvent of formula (I) and an alkyl lactate of formula (II): wherein R1 is C5-C19 alkyl and R2 is methyl, ethyl, propyl, butyl or a mixture thereof; wherein R3 is C1-C16 alkyl. The concentrate optionally includes a surfactant. The concentrate exhibits very good low temperature stability and dilution stability. A method for preparing the concentrate; and an emulsion that can be obtained by mixing water, abamectin, the amide of formula (I) and the alkyl lactate of formula (II), is also provided.

Abstract: Various salts of tranexamic acid esters compounds are described, along with compositions including such compounds. Methods of use for treatment of external surfaces (e.g. skin) and processes of producing the compounds and compositions are also described.

Abstract: The present invention provides a compound having the structure of Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, or isomer thereof, for the controlled delivery and release of Agent.

Abstract: Provided herein are compositions, systems, and methods for treating wounds with the combination of statins and cholesterol to help prevent and reduce scar formation.

Abstract: The present invention relates to the detection or diagnosis of infection or inflammation in a patient. In particular, the invention provides methods that allow the detection of markers in a sample from a patient or subject, such as a blood sample, which will indicate whether the patient or subject has an infection or has an inflammatory response.

Abstract: The invention relates to a method for producing glycerides of 3-hydroxybutyric acid as well as the products thus obtained and their use.

Abstract: Provided herein are KRAS modulating compounds, such as compounds of Formula (I), (I-A), (I-B), (I-C), (I-C*), (I-D), (I-E), (I-F), (I-G), (I-H), (I-I), (I-J), or pharmaceutically acceptable salts, solvates, stereoisomers, atom labelled, or tautomers of any one thereof. The compounds provided herein are useful for modulating KRAS G12D and/or other G12 mutants.

Abstract: A composition for treating dry skin includes therapeutically active concentrations of one or more skin protecting lipids in an oleaginous base. The skin protecting lipids can include a sphingolipid and at least one oil. The composition is intended for application on the skin surrounding the eyes. The composition is configured to form a protective, occlusive layer that can moisturize the skin and reduce inflammation and itching without stinging, burning, or stripping the skin. According to an exemplary embodiment, the composition is formulated as a high viscosity ointment or gel.

Abstract: An alcohol-free lotion for the topical application having antiseptic properties is made by combining an aqueous phase comprising formaldehyde and at least one humectant with an oil phase comprising at least one surfactant and at least one oil; wherein the at least one humectant is present in the aqueous phase in the range of from 30 to 75 wt. %., wherein formaldehyde is present in the aqueous phase in the range of from about 1.0 to 20.0 wt. %; wherein the surfactant is present in the oil phase in the range of from about 30 to 60 wt. %; wherein the aqueous phase to oil phase ratio is from about 10:1 to 4:1; and wherein the lotion free of the odor of formaldehyde.